HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fowler, E. G. Articles by Spencer, M. J. Search for Related Content PubMed PubMed Citation Articles by Fowler, E. G. Articles by Spencer, M. J. Related Collections Muscle disease All Clinical trials Clinical trials Observational study (Cohort, Case control)

Pilot trial of albuterol in Duchenne and Becker muscular dystrophy

From the UCLA Duchenne Muscular Dystrophy Research Center (Drs. Fowler, Graves, and Spencer), and Departments of Orthopaedic Surgery (Dr. Fowler), Neurology (Dr. Graves), and Pediatrics (Drs. Wetzel and Spencer), David Geffen School of Medicine at UCLA, Los Angeles, CA.

Address correspondence and reprint requests to Dr. Melissa J. Spencer, UCLA Department of Pediatrics, Duchenne Muscular Dystrophy Research Center, 621 Charles Young Drive South, Los Angeles, CA 90095-1606; e-mail: Mspencer{at}mednet.ucla.edu

The authors conducted a randomized, crossover, double-blind, placebo-controlled pilot study of albuterol in nine boys with dystrophinopathies. Primary outcomes were 1) isometric knee extensor and flexor strength; and 2) manual muscle testing (MMT). Isometric knee extensor strength and MMT scores were significantly higher in patients taking albuterol vs placebo. Therefore, 12-week treatment with extended-release albuterol may increase strength in patients with dystrophinopathies. A larger, double-blind, randomized study is necessary to confirm these results.

Received May 30, 2003. Accepted in final form December 15, 2003.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the March 23 issue to find the title link for this article.

This article has been cited by other articles:

				J. G. Ryall, J. D. Schertzer, K. T. Murphy, A. M. Allen, and G. S. Lynch Chronic {beta}2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2587 - H2595. [Abstract] [Full Text] [PDF]

				G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]

				C. L. Skura, E. G. Fowler, G. T. Wetzel, M. Graves, and M. J. Spencer Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy Neurology, January 8, 2008; 70(2): 137 - 143. [Abstract] [Full Text] [PDF]

				J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]

				S. D. Colan Evolving Therapeutic Strategies for Dystrophinopathies: Potential for Conflict Between Cardiac and Skeletal Needs Circulation, November 1, 2005; 112(18): 2756 - 2758. [Full Text] [PDF]

				L. J. Harcourt, A. G. Holmes, P. Gregorevic, J. D. Schertzer, N. Stupka, D. R. Plant, and G. S. Lynch Interleukin-15 Administration Improves Diaphragm Muscle Pathology and Function in Dystrophic mdx Mice Am. J. Pathol., April 1, 2005; 166(4): 1131 - 1141. [Abstract] [Full Text] [PDF]